Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be ...

Q2 2025 Earnings Call Transcript August 12, 2025 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is ...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

Theravance Biopharma's Q2 2025 earnings show robust growth with YUPELRI sales up 22%, a $225M TRELEGY royalty sale, and progress in the pivotal CYPRESS trial.